Richter said FY 2025 pharma revenues rose 8.2% to HUF 914.0bn, including Q4 2025 pharma revenues up 12.5% to HUF 245.2bn. FY 2025 gross profit (pharma) increased 8% to HUF 635.0bn, with gross margin at 69.5%. Clean EBIT (pharma) grew 14% to HUF 305.0bn in FY 2025, and rose 37% to HUF 92.0bn in Q4. Reported EBIT increased 12.1% to HUF 292.9bn in FY 2025. Net profit attributable to the owners of the parent fell 3% to HUF 232.3bn, which Richter said reflected HUF 10.8bn in net financial expenses driven by HUF 25.0bn in FX losses. Free cash flow (before M&A) rose 2% to HUF 250.0bn; Richter also reported paying a regular annual dividend of HUF 93.0bn in Q2. By business, CNS revenues increased 9% in FY 2025, supported by steady prescription growth for Vraylar (AbbVie net sales up 11% to USD 3.6bn) and Reagila sales up 7%. Women’s Healthcare sales grew 15% for FY 2025, with momentum cited for Drovelis, Ryeqo, Lenzetto and Evra, and the share of contraceptives declining below 60% of total Women’s Healthcare revenues. Biotechnology revenues rose 19% in FY 2025, while GenMed revenues were slightly negative for the full year. For 2026, Richter guided for high-single-digit growth in both revenues and Clean EBIT at constant exchange rates, citing ongoing efficiency programs and cost discipline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gedeon Richter plc published the original content used to generate this news brief on February 27, 2026, and is solely responsible for the information contained therein.